Subclasses of cyclic GMP-specific phosphodiesterase and their role in regulating the effects of atrial natriuretic factor.
Two subclasses of cyclic guanosine monophosphate (GMP)-specific phosphodiesterases were identified in vascular tissue from several beds. The activity of one subclass (phosphodiesterase IB) was stimulated severalfold by calmodulin and selectively inhibited by the phosphodiesterase inhibitor TCV-3B. The activity of the other subclass (phosphodiesterase IC) was not stimulated by calmodulin and was selectively inhibited by the phosphodiesterase inhibitor M&B 22,948. To assess the involvement of both subclasses in regulating cyclic GMP-dependent responses, the ability of TCV-3B and M&B 22,948 to potentiate the in vitro and in vivo responses to the endogenous guanylate cyclase stimulator atrial natriuretic factor (ANF) was evaluated. Both TCV-3B and M&B 22,948 relaxed isolated rabbit aortic and pulmonary artery rings and also potentiated the relaxant effect of ANF. In addition, both inhibitors produced small increases in urine flow and sodium excretion in anesthetized rats and potentiated the diuretic and natriuretic responses to exogenous ANF. M&B 22,948 (30 micrograms/kg/min) produced a threefold increase in the natriuretic response to simultaneously administered ANF, and TCV-3B (10 micrograms/kg/min) produced a twofold increase in the response to ANF. The results of the present experiments suggest that both the calmodulin-sensitive and calmodulin-insensitive subclasses of cyclic GMP-specific phosphodiesterase play a role in regulating the in vitro and in vivo response to ANF.
Weishaar
R E
RE
Department of Pharmacology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan.
Kobylarz-Singer
D C
DC
Keiser
J
J
Haleen
S J
SJ
Major
T C
TC
Rapundalo
S
S
Peterson
J T
JT
Panek
R
R
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors / Q000145:classification* / Q000502:physiology; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000494:pharmacology*; D001808:Blood Vessels / Q000201:enzymology; D004285:Dogs; D004357:Drug Synergism; D007700:Kinetics; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000145:classification / Q000494:pharmacology*; D011688:Purinones / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D014748:Vinca Alkaloids / Q000494:pharmacology
D010726:Phosphodiesterase Inhibitors; D011688:Purinones; D014748:Vinca Alkaloids; C013983:vinpocetine; D009320:Atrial Natriuretic Factor; D015106:3',5'-Cyclic-GMP Phosphodiesterases; C011145:zaprinast